The Association of the British Pharmaceutical Industry (ABPI) has lauded the industry’s contributions to UK research and development (R&D), releasing the figures for 2019.
ABPI has summarised the data gathered in Disclosure UK, “which details aggregate R&D spend, as well as individual payments and benefits in kind made to UK healthcare professionals (HCPs) and healthcare organisations (HCOs)”.
Although some detail is missing compared to previous years, due the pressure of COVID-19 on NHS staff, the data paint an encouraging picture of the industry’s willingness to invest in UK R&D.
“The available 2019 figures show:
- £538.2 million has been disclosed by pharmaceutical companies for 2019, compared with £503million in 2018 (excluding joint-working*)
- £381.2 million of this was spent on R&D, compared with £377.3million in 2018
- £157 million of this was spent on non-R&D collaborations with HCPs and HCOs in 2019, vs £125.7 million in 2018 (excluding joint-working) Much of this increase was due to payments to healthcare organisations
11 new companies have disclosed payments this year, bringing the total number of companies using Disclosure UK to 143″
ABPI Chief Executive, Richard Torbett said:
“The 2019 disclosure data available so far tells a hugely positive story – the third successive year of increasing investment by industry in UK R&D. This can only be a good thing for patients and the NHS.”
The news came at the same time as the UK Government’s launch of the UK Research and Development Roadmap. The Roadmap represents the Government’s plan to raise UK R&D spend to £22 billion by 2024/25. A key aim of the Roadmap is to:
“increase our investment in research, unlocking new discoveries and applying research to solving our most pressing problems in government, industry and across society”